MED vs. HLF, USNA, NUS, NATR, VERU, EL, IPAR, PBH, FARM, and JVA
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include Herbalife (HLF), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Veru (VERU), Estée Lauder Companies (EL), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Farmer Bros. (FARM), and Coffee (JVA).
Medifast (NYSE:MED) and Herbalife (NYSE:HLF) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
Medifast currently has a consensus target price of $53.50, indicating a potential upside of 107.85%. Herbalife has a consensus target price of $10.50, indicating a potential upside of 1.94%. Given Medifast's stronger consensus rating and higher possible upside, research analysts plainly believe Medifast is more favorable than Herbalife.
Medifast has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Herbalife has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Herbalife received 323 more outperform votes than Medifast when rated by MarketBeat users. Likewise, 67.62% of users gave Herbalife an outperform vote while only 63.94% of users gave Medifast an outperform vote.
In the previous week, Herbalife had 6 more articles in the media than Medifast. MarketBeat recorded 7 mentions for Herbalife and 1 mentions for Medifast. Herbalife's average media sentiment score of 0.89 beat Medifast's score of -0.12 indicating that Herbalife is being referred to more favorably in the news media.
95.5% of Medifast shares are held by institutional investors. 2.5% of Medifast shares are held by company insiders. Comparatively, 0.9% of Herbalife shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Medifast has a net margin of 7.55% compared to Herbalife's net margin of 2.70%. Medifast's return on equity of 36.64% beat Herbalife's return on equity.
Herbalife has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.
Summary
Medifast beats Herbalife on 9 of the 17 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
